Gut bacteria may supercharge lung cancer therapy

NCT ID NCT07534033

Recruiting now Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a daily probiotic (Lactobacillus rhamnosus LR607) for three months can make standard chemoimmunotherapy work better for people with stage IIB-IIIB non-small cell lung cancer before they have surgery. About 46 adults will take the probiotic alongside their cancer treatment and be monitored for tumor response, side effects, and changes in gut bacteria. The goal is to see if this combination can shrink tumors more effectively and improve surgical outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC DIAGNOSED BY HISTOLOGY OR CYTOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

A MULTIDISCIPLINARY TEAM ASSESSMENT DETERMINED THAT THE PATIENT WAS A SUITABLE CANDIDATE FOR RADICAL SURGICAL RESECTION AJCC IS CLASSIFIED AS IB-IIIC NSCLC DIAGNOSED BY HISTOLOGY OR CYTOLOGY OVERALL LUNG FUNCTION IS ADEQUATE FOR THE PLANNED LUNG RESECTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhu Jiang Hospital of Southern Medical University
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••